Century Therapeutics, Inc.IPSCNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank48
5Y CAGR-36.4%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-36.4%/yr
Long-term compound
Percentile
P48
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.57% |
| Q3 2025 | -18.01% |
| Q2 2025 | -10.99% |
| Q1 2025 | -9.51% |
| Q4 2024 | 7.89% |
| Q3 2024 | 0.03% |
| Q2 2024 | 16.22% |
| Q1 2024 | 0.54% |
| Q4 2023 | -13.04% |
| Q3 2023 | 17.87% |
| Q2 2023 | -8.72% |
| Q1 2023 | -2.68% |
| Q4 2022 | -1.21% |
| Q3 2022 | 5.73% |
| Q2 2022 | 15.56% |
| Q1 2022 | -2.75% |
| Q4 2021 | 11.52% |
| Q3 2021 | 3.23% |
| Q2 2021 | 23.15% |
| Q1 2021 | 23.57% |
| Q4 2020 | 15.08% |
| Q3 2020 | 27.44% |
| Q2 2020 | 6.81% |
| Q1 2020 | 0.00% |